The modern regenerative technologies in the treatment of osteoarthritis of the large joints


  • O.I. Olifirenko Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine; Small private enterprise Firm “Rehabilitation”, Kyiv, Ukraine
  • H.I. Hertsen Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine
  • O.S. Movchan Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine
  • R.O. Serhiienko Small private enterprise Firm “Rehabilitation”, Kyiv, Ukraine
  • Yu.Ye. Bursuk Small private enterprise Firm “Rehabilitation”, Kyiv, Ukraine; Institute of Traumatology and Orthopedics of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine



osteoarthritis, platelet-rich plasma, bone marrow concentrate, regenerative medicine


In 2018–2021, 114 patients with the diagnosis of knee osteoarthritis of grade 1–3 according to the Kellgren and Lawrence classification underwent treatment. The diagnosis was verified radiologically, specified by magnetic resonance imaging, intraoperative arthroscopically. The patients underwent treatment according to the developed algorithm using minimally invasive regenerative techniques: platelet-rich plasma, bone marrow concentrate (BMC) and hyaluronic acid. The control group was not provided for a number of ethical and technical reasons. Based on the assumption that “osteoarthritis is a progressive disease”, stable positive changes in the subjective assessment of the knee joint and the absence of signs of progression during instrumental examination can be considered a success of this technique. Treatment outcomes were assessed in 1, 3, 6, 9 and 12 months using the Knee and Osteoarthritis Outcome Score, Western Ontario McMaster Universities OA Index, International Knee Documentation Committee, data from repeated magnetic resonance imaging and direct macroscopic examination du-
ring repeated arthroscopies. According to the international subjective scales for assessing joint function and pain, patients after treatment with injectable regenerative agents showed a steady improvement in follow-up of up to 12 months. Based on the clinical results, it can be concluded that the developed treatment regimen is a mo-dern regenerative therapy that helps to repair damaged areas of the musculoskeletal system due to the effect of a balanced complex of mesenchymal stem cells, growth factors, cytokines. The developed algorithm of obtaining and applying BMC is safe and rational.


Download data is not yet available.


Litwic A., Edwards M.H., Dennison E.M., Cooper C. Epidemiology and burden of osteoarthritis. Br. Med. Bull. 2013. 105. 185-99. doi: 10.1093/bmb/lds038.

Lawrence R.C., Felson D.T., Helmick C.G., Arnold L.M., Choi H., Deyo R.A., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part 2. Arthritis Rheum. 2008. 58. 26-35.

Cassano J.M., Kennedy J.G., Ross K.A., et al. Bone marrow concentrate and platelet-rich plasma differ in cell distribution and interleukin 1 receptor antagonist protein concentration. Knee Surg. Sports Traumatol. Arthrosc. 2016. DOI: 10.1007/s00167-016-3981-9.



How to Cite

Olifirenko, O., Hertsen, H., Movchan, O., Serhiienko, R., & Bursuk, Y. (2022). The modern regenerative technologies in the treatment of osteoarthritis of the large joints. TRAUMA, 23(2), 40–46.



To General Practitioner

Most read articles by the same author(s)